Literature DB >> 9761512

Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.

G Coen1, P Ballanti, E Bonucci, S Calabria, M Centorrino, V Fassino, M Manni, D Mantella, S Mazzaferro, I Napoletano, D Sardella, F Taggi.   

Abstract

BACKGROUND: Renal osteodystrophy includes a number of low and high turnover bone histologic patterns which require a bone biopsy for their full identification. The role of intact PTH and several classical and more recent bone markers in the non-invasive diagnosis of renal bone disease in patients with CRF in HD requires further definition since available published data are limited.
METHODS: In addition to intact PTH, alkaline phosphatase (AP) and osteocalcin (BGP), bone alkaline phosphatase isoenzyme (BALP), tartrate resistant acid phosphatase (TRAP), C-terminal cross-linked peptide of collagen type 1 (ICTP) and deoxypyridinoline (DPD) were measured in the serum of 41 patients on haemodialysis, subjected at the same time to transiliac bone biopsy for histomorphometric, histodynamic and aluminium histochemical examination. Histodynamic evaluation following double tetracycline label, was carried out in 37 patients. The patients had no evidence of active cytolytic and cholestatic liver disease and a history of very limited aluminium exposure.
RESULTS: The patients had differing degrees of hyper-parathyroidism, with intact PTH ranging from normal to very elevated levels. Serum values of the markers BGP, ICTP and DPD, normally excreted through the kidneys, were on average very high. The correlation coefficients of the humoral parameters vs dynamic variables, such as BFR/BS, were high. The highest values were: intact PTH 0.798, AP 0.900, BALP 0.891, ICTP 0.807. The patients, grouped in low turnover osteodystrophy (LTO; 9), mixed osteodystrophy (MO; 9) and prevalent hyperparathyroidism (HP; 23), showed significant difference in the levels of most humoral and static and dynamic parameters (ANOVA). Bone aluminium histochemistry was negative in all cases. Discrimination of LTO patients from the other groups by humoral parameters, at the highest value of accuracy, showed 100% sensitivity and 93.7% specificity with a cut-off of 12.9 ng/ml for BALP; 88.9% sensitivity and 93.7% specificity with a cut-off of 21.5 ng/ml for DPD, and 88.9% sensitivity and 90.6% specificity with a cut-off of 79.7 pg/ml for intact PTH. The other markers had lower values. A standardized z-score approach for evaluation of all humoral parameters was also carried out. Using all variables, a correct classification of MO/HP and of LTO was possible in 93.8 and 88.9% of the cases, respectively. Predictive power was 96.8 and 80%, respectively for MO/HP and LTO. When the only variables used were intact PTH and BALP, a correct classification of MO/HP and LTO was possible in 90.6% and 88.9%, respectively. Predictive value of MO/HP was 96.7% and for LTO 72.7%. Predictive values using PTH and AP were 96.3% and 57.2%, respectively.
CONCLUSION: Intact PTH and several relatively new bone markers are of certain value in the non-invasive diagnosis of renal osteodystrophy. However some of the humoral markers carry the same quality of information and the use of intact PTH and BALP may be adequate in the discrimination of bone histologic patterns. In cases exempt from liver disease, PTH and AP may be used as a less costly alternative. Bone biopsy could be chiefly limited to cases with borderline humoral values and to all those with a suspected aluminium overload.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761512     DOI: 10.1093/ndt/13.9.2294

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  32 in total

Review 1.  Acid phosphatases.

Authors:  H Bull; P G Murray; D Thomas; A M Fraser; P N Nelson
Journal:  Mol Pathol       Date:  2002-04

Review 2.  Biomarkers Predicting Bone Turnover in the Setting of CKD.

Authors:  Pieter Evenepoel; Etienne Cavalier; Patrick C D'Haese
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 3.  Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics.

Authors:  Erin M B McNerny; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

4.  The utility of circulating markers to predict bone loss across the CKD spectrum.

Authors:  Thomas L Nickolas
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-19       Impact factor: 8.237

Review 5.  Can one evaluate bone disease in chronic kidney disease without a biopsy?

Authors:  Revekka Babayev; Thomas L Nickolas
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

6.  Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients.

Authors:  Jan Mares; Kristina Ohlidalova; Sylvie Opatrna; Jiri Ferda
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

7.  Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.

Authors:  Syazrah Salam; Orla Gallagher; Fatma Gossiel; Margaret Paggiosi; Arif Khwaja; Richard Eastell
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

Review 8.  Bone kidney interactions.

Authors:  Thomas L Nickolas; Sophie A Jamal
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 9.  Chronic kidney disease and osteoporosis: evaluation and management.

Authors:  Paul D Miller
Journal:  Bonekey Rep       Date:  2014-06-25

10.  The association between parathyroid hormone and mortality in dialysis patients is modified by wasting.

Authors:  Christiane Drechsler; Vera Krane; Diana C Grootendorst; Eberhard Ritz; Karl Winkler; Winfried März; Friedo Dekker; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2009-05-27       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.